Additionally, by binding to GLP-1 receptors in enteric neurons and endocrine cells, these agents slow gastric motility, reduce acid secretion, and modulate appetite through satiety signaling to the hypothalamus [3]
[18] Other research suggests that several pharmaceutical companies, including AstraZeneca, Zealand Pharma, Roche, and Amgen, are expected to enter the GLP-1 market, with multiple drug launches planned between 2027 and 2032
Across multiple SUSTAIN trials, patients treated with semaglutide 0.5 mg or 1.0 mg weekly demonstrated statistically significant reductions in total cholesterol and LDL-C compared to placebo and several active comparators
The glucagon arm is the third lever: rather than only reducing energy intake through appetite, glucagon agonism raises energy expenditure and pushes the liver to mobilize stored fat
If your diabetes is well-controlled, either through lifestyle changes like diet and exercise, an injectable medication, or an oral drug, you are most likely a candidate to give blood, plasma or other blood products
Fibrosis and cirrhosis: Scarring of the liver that develops over years of ongoing damage